Patisiran for intravenous infusion (Onpattro™)

OFFICE ADMINISTRATION

Indications for Prior Authorization:
  • Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Patients must meet the following criteria for the indication(s) above:
  • Diagnosis of polyneuropathy of hereditary amyloid transthyretin-mediated amyloidosis (hATTR), AND
  • Is prescribed by or in consultation with a neruologist, geneticist, or a physician who specializes in the treatment of amyloidosis, AND
  • The patient is 18 years of age or older, AND
  • The patient has a documented transthyretin (TTR) mutation verified by genetic testing, AND
  • The patient has symptomatic peripheral neuropathy (e.g., reduced motor strength/coordination, impaired sensation [e.g., pain, temperature, vibration, touch])
Dosing:
  • For patients weighing < 100 kg: the recommended dosage is 0.3 mg/kg intravenously (IV) once every 3 weeks
  • For patients weighing ≥ 100 kg: the recommended dosage is 30 mg IV once every 3 weeks 
  • Onpattro should be administered by a healthcare professional along with premedications to reduce risk of infusion-related reactions
Approval:
  • One year

Last review date: June 10, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone